Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab plus platinum-etoposide chemotherapy for first-line advanced esophageal small cell carcinoma
ChiCTR2500101345Phase 4Recruiting
- Sponsor
- Anyang Cancer Hospital
- Start
- Apr 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of adebrelimab in small cell carcinoma of the esophagus (SCEC), sponsored by Anyang Cancer Hospital. Primary endpoint: Progression-free survival. Started Apr 2025; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
small cell carcinoma of the esophagus (SCEC)
Beyond the preview
Go deeper on ChiCTR2500101345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500101345.